[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate | 54378-86-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: [(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylhept-5-en-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] hydrogen sulfate
• CAS: 54378-86-8
• 化学式: C₂₇H₄₄O₄S
• 分子量: 464.7
• InChiKey: FGBYFPSXXVLWQV-DPAQBDIFSA-N

物化性质

• 密度：
  1.13±0.1 g/cm3(Predicted)
• 溶解度：
  甲醇（轻微溶解，超声处理），水（轻微溶解，加热，超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  7.7
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  72
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] USE OF OXYGENATED CHOLESTEROL SULFATES FOR TREATING AT LEAST ONE OF INSULIN RESISTANCE, DIABETES, AND PREDIABETES<br/>[FR] UTILISATION DE SULFATES DE CHOLESTÉROL OXYGÉNÉS À DES FINS DE TRAITEMENT DE LA RÉSISTANCE À L'INSULINE ET/OU DU DIABÈTE ET/OU DU PRÉDIABÈTE
  申请人：DURECT CORP

  公开号：WO2021263185A1

  公开（公告）日：2021-12-30

  Aspects of the present disclosure include methods for treating at least one of insulin resistance, diabetes, and prediabetes, and, optionally, also non-alcoholic steatohepatitis (NASH). In practicing the subject methods, an effective amount of at least one compound selected from 25-hydroxycholesterol-3-sulfate (25HC3S), 25- hydroxycholesterol-disulfate (25HCDS), 27-hydroxycholesterol-3-sulfate (27HC3S), 27- hydroxycholesterol-disulfate (27HCDS), 24-hydroxycholesterol-3-sulfate (24HC3S), 24- hydroxycholesterol-disulfate (24HCDS), and 24,25-epoxycholesterol-3-sulfate, or salt thereof is administered to the subject.

  本公开的方面包括用于治疗胰岛素抵抗、糖尿病和糖尿病前期以及可选地治疗非酒精性脂肪性肝病（NASH）的方法。在实施该方法时，向受试者施用至少一种选自25-羟基胆固醇-3-硫酸酯（25HC3S）、25-羟基胆固醇-二硫酸酯（25HCDS）、27-羟基胆固醇-3-硫酸酯（27HC3S）、27-羟基胆固醇-二硫酸酯（27HCDS）、24-羟基胆固醇-3-硫酸酯（24HC3S）、24-羟基胆固醇-二硫酸酯（24HCDS）和24,25-环氧胆固醇-3-硫酸酯或其盐的有效量化合物。
• INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS
  申请人：President and Fellows of Harvard College

  公开号：EP3310367A1

  公开（公告）日：2018-04-25
• REAL TIME MULTIPOINT ASSAY FOR OPTIMIZING PERFORMANCE
  申请人：Cohen Barb Ariel

  公开号：US20120252000A1

  公开（公告）日：2012-10-04

  Described herein are methods of optimizing the performance of a mammalian semen sample with respect to outcomes such as fertility, using a multipoint assay to determine an optimum time point for preparing the semen sample for use in insemination. The multipoint assay is based upon a kinetic model of biomarker expression during sperm capacitation relative to the outcome of interest.
• [EN] PREPARATIONS OF DERIVED EXTRACELLULAR VESICLES, ASSAYS, AND METHODS TO MODIFY THERAPEUTIC OUTCOMES USING SUCH PREPARATIONS<br/>[FR] PRÉPARATIONS DE VÉSICULES EXTRACELLULAIRES DÉRIVÉES, DOSAGES, ET PROCÉDÉS VISANT À MODIFIER LES RÉSULTATS THÉRAPEUTIQUES DE CES PRÉPARATIONS
  申请人：COHEN BARB ARIEL

  公开号：WO2015143113A1

  公开（公告）日：2015-09-24

  A method for altering the properties of extracellular vesicles and exosomes for use in diagnosis and therapeutics is disclosed, through their production by primary cell culture under Applicant's specific controlled conditions. A mammalian ejaculate is provided and sperm therefrom are incubated, during which time aliquots are evaluated for production of vesicles engineered to contain the cargo of choice and targeted to the desired application through adjustment of the surface receptor complement. For example, vesicle-borne Fc receptors act as decoys to protect sperm from antibodies in the female tract and vesicles additionally deliver regulatory molecules to modulate tract function, enabling the ability to control release and to engineer sperm-derived vesicle/ exosome structures to be used in diagnosis of infertility and in production of sperm doses of superior performance.
• [EN] INDUCTION OF LAMINA PROPRIA REGULATORY T CELLS<br/>[FR] INDUCTION DE LYMPHOCYTES T RÉGULATEURS LAMINA PROPRIA
  申请人：HARVARD COLLEGE

  公开号：WO2016209806A1

  公开（公告）日：2016-12-29

  Described herein are methods and compositions for the induction of the production of regulatory T cells and for the treatment and/or prevention of diseases associated with pathological immune responses, such as inflammatory bowel diseases.